ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
profitability factor · long-only model fund

Foundry Healthcare Return on Equity Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FROHHYPOTHETICAL MODEL
Since ’99
−96%
Expense Ratio
0.45%
placeholder
Holdings
95
cap-weighted
Inception
May 2022
placeholder
Full Sharpe
-0.16
Ann. Return (LS)
-4.7%
Ann. Volatility
29.6%
Max Drawdown
-96.7%
Test Sharpe ’19–26
-0.33
Test FF5 α (ann.)
-7.6%
vs Fama-French 5
Test FF5 α t-stat
-1.55
not significant
Monthly turnover
9%
of the long leg, per rebalance
Cumulative return (LS)
-96%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.60
what this fund holds
Long leg ann. return
8.6%
buyable, long-only
Long-short Sharpe
-0.16
requires shorting
Bottom bucket ann. return
13.4%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

95 of 95 · 100.0% of book
TickerCompanySectorMarket capWeight
1LLY
ELI LILLY & COHealthcare$1.11T
35.88%
2JNJ
JOHNSON & JOHNSONHealthcare$609.12B
19.68%
3AMGN
AMGEN INCHealthcare$197.69B
6.39%
4GILD
GILEAD SCIENCES INCHealthcare$166.72B
5.39%
5BMY
BRISTOL MYERS SQUIBB COHealthcare$124.04B
4.01%
6VRTX
VERTEX PHARMACEUTICALS INCHealthcare$123.26B
3.98%
7COR
CENCORA INCHealthcare$59.91B
1.94%
8IDXX
IDEXX LABORATORIES INCHealthcare$44.76B
1.45%
9TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTDHealthcare$37.30B
1.21%
10A
AGILENT TECHNOLOGIES INCHealthcare$37.13B
1.20%
11ALNY
ALNYLAM PHARMACEUTICALS INCHealthcare$35.71B
1.15%
12IQV
IQVIA HOLDINGS INCHealthcare$34.42B
1.11%
13ZTS
ZOETIS INCHealthcare$32.10B
1.04%
14DXCM
DEXCOM INCHealthcare$29.58B
0.96%
15RMD
RESMED INCHealthcare$28.86B
0.93%
16GEHC
GE HEALTHCARE TECHNOLOGIES INCHealthcare$28.69B
0.93%
17ILMN
ILLUMINA INCHealthcare$28.24B
0.91%
18WST
WEST PHARMACEUTICAL SERVICES INCHealthcare$25.31B
0.82%
19INCY
INCYTE CORPHealthcare$23.42B
0.76%
20UTHR
UNITED THERAPEUTICS CORPHealthcare$22.74B
0.73%
21GH
GUARDANT HEALTH INCHealthcare$20.67B
0.67%
22NBIX
NEUROCRINE BIOSCIENCES INCHealthcare$17.18B
0.56%
23THC
TENET HEALTHCARE CORPHealthcare$16.79B
0.54%
24BBIO
BRIDGEBIO PHARMA INCHealthcare$15.94B
0.52%
25MEDP
MEDPACE HOLDINGS INCHealthcare$15.36B
0.50%
26SOLV
SOLVENTUM CORPHealthcare$14.08B
0.45%
27EXEL
EXELIXIS INCHealthcare$14.06B
0.45%
28PODD
INSULET CORPHealthcare$11.36B
0.37%
29EHC
ENCOMPASS HEALTH CORPHealthcare$11.13B
0.36%
30KRYS
KRYSTAL BIOTECH INCHealthcare$10.46B
0.34%
31CYTK
CYTOKINETICS INCHealthcare$9.98B
0.32%
32HALO
HALOZYME THERAPEUTICS INCHealthcare$9.23B
0.30%
33UHS
UNIVERSAL HEALTH SERVICES INCHealthcare$9.15B
0.30%
34TGTX
TG THERAPEUTICS INCHealthcare$8.40B
0.27%
35IBRX
IMMUNITYBIO INCHealthcare$8.04B
0.26%
36LQDA
LIQUIDIA CORPHealthcare$7.11B
0.23%
37LNTH
LANTHEUS HOLDINGS INCHealthcare$7.00B
0.23%
38CHE
CHEMED CORPHealthcare$6.77B
0.22%
39PTCT
PTC THERAPEUTICS INCHealthcare$6.52B
0.21%
40SHC
SOTERA HEALTH COHealthcare$5.06B
0.16%
41ACAD
ACADIA PHARMACEUTICALS INCHealthcare$4.38B
0.14%
42CON
CONCENTRA GROUP HOLDINGS PARENT INCHealthcare$4.04B
0.13%
43DOCS
DOXIMITY INCHealthcare$3.94B
0.13%
44CPRX
CATALYST PHARMACEUTICALS INCHealthcare$3.85B
0.12%
45BKD
BROOKDALE SENIOR LIVING INCHealthcare$3.58B
0.12%
46OGN
ORGANON & COHealthcare$3.55B
0.11%
47RARE
ULTRAGENYX PHARMACEUTICAL INCHealthcare$2.88B
0.09%
48GRDN
GUARDIAN PHARMACY SERVICES INCHealthcare$2.57B
0.08%
49TMDX
TRANSMEDICS GROUP INCHealthcare$2.56B
0.08%
50BCRX
BIOCRYST PHARMACEUTICALS INCHealthcare$2.36B
0.08%
51MD
PEDIATRIX MEDICAL GROUP INCHealthcare$2.15B
0.07%
52HTFL
HEARTFLOW INCHealthcare$2.15B
0.07%
53AVAH
AVEANNA HEALTHCARE HOLDINGS INCHealthcare$2.11B
0.07%
54AUPH
AURINIA PHARMACEUTICALS INCHealthcare$2.05B
0.07%
55ADMA
ADMA BIOLOGICS INCHealthcare$2.02B
0.07%
56URGN
UROGEN PHARMA LTDHealthcare$1.96B
0.06%
57ANAB
ANAPTYSBIO INCHealthcare$1.69B
0.05%
58INVA
INNOVIVA INCHealthcare$1.60B
0.05%
59XERS
XERIS BIOPHARMA HOLDINGS INCHealthcare$1.52B
0.05%
60INSP
INSPIRE MEDICAL SYSTEMS INCHealthcare$1.46B
0.05%
61PAHC
PHIBRO ANIMAL HEALTH CORPHealthcare$1.35B
0.04%
62NVAX
NOVAVAX INCHealthcare$1.35B
0.04%
63IRMD
IRADIMED CORPHealthcare$1.24B
0.04%
64COLL
COLLEGIUM PHARMACEUTICAL INCHealthcare$1.17B
0.04%
65MGTX
MEIRAGTX HOLDINGS PLCHealthcare$1.15B
0.04%
66NUTX
NUTEX HEALTH INCHealthcare$1.12B
0.04%
67VOR
VOR BIOPHARMA INCHealthcare$980M
0.03%
68TBPH
THERAVANCE BIOPHARMA INCHealthcare$873M
0.03%
69PHAT
PHATHOM PHARMACEUTICALS INCHealthcare$873M
0.03%
70ZVRA
ZEVRA THERAPEUTICS INCHealthcare$755M
0.02%
71RIGL
RIGEL PHARMACEUTICALS INCHealthcare$750M
0.02%
72CRMD
CORMEDIX INCHealthcare$661M
0.02%
73TOI
ONCOLOGY INSTITUTE INCHealthcare$535M
0.02%
74CTEV
CLARITEV CORPHealthcare$518M
0.02%
75XOMA
XOMA ROYALTY CORPHealthcare$504M
0.02%
76NRC
NRC HEALTHHealthcare$491M
0.02%
77PBYI
PUMA BIOTECHNOLOGY INCHealthcare$434M
0.01%
78ABEO
ABEONA THERAPEUTICS INCHealthcare$399M
0.01%
79STRO
SUTRO BIOPHARMA INCHealthcare$391M
0.01%
80EOLS
EVOLUS INCHealthcare$377M
0.01%
81ELMD
ELECTROMED INCHealthcare$349M
0.01%
82CV
CAPSOVISION INCHealthcare$335M
0.01%
83FHTX
FOGHORN THERAPEUTICS INCHealthcare$305M
0.01%
84QTTB
Q32 BIO INCHealthcare$255M
0.01%
85SRZN
SURROZEN INCHealthcare$255M
0.01%
86RNAC
CARTESIAN THERAPEUTICS INCHealthcare$243M
0.01%
87KPTI
KARYOPHARM THERAPEUTICS INCHealthcare$216M
0.01%
88PDEX
PRO DEX INCHealthcare$183M
0.01%
89OWLT
OWLET INCHealthcare$162M
0.01%
90RCEL
AVITA MEDICAL INCHealthcare$157M
0.01%
91PIII
P3 HEALTH PARTNERS INCHealthcare$78M
0.00%
92ATRA
ATARA BIOTHERAPEUTICS INCHealthcare$76M
0.00%
93CLNN
CLENE INCHealthcare$76M
0.00%
94SCLX
SCILEX HOLDING COHealthcare$72M
0.00%
95INKT
MINK THERAPEUTICS INCHealthcare$53M
0.00%

Full long-leg book as of July 2026 · cap-weighted · total market cap $3.09T. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

1 sectors
Healthcare
100.0%

Portfolio Style

Size × value map of the long-leg book

95 classified
Value
Blend
Growth
Large
Mid
Small
14%10
39%16
44%13
<1%8
<1%3
<1%5
<1%5
<1%5
<1%3

Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 99% toward Large, 65% toward Growth. +3% unclassified (27 missing size/value). Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt99% → Large
SmallLarge
Value ↔ growth tilt65% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 95 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
3
Failed
3
Not tested
1
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

  • With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.

    Required
    >= 75.0%
    Actual
    52.7%
    Margin
    -22.3%
  • No more than 25% of total assets may be invested in the securities of any one issuer.

    Required
    <= 25.0%
    Actual
    35.9%
    Margin
    -10.9%
  • Days required to liquidate the largest position at 20% of one day's dollar volume.

    Required
    <= 7.0 days
    Actual
    unbounded
    Margin
Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

No verdict sits within 1.0pp of its limit.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 95 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
0.9 (95% CI 0.6-1.0)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
8.5%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
0.88x
within
parametric
0.91x
within
cornish fisher
0.81x
within

The estimators agree, which is mild evidence the number isn’t an artefact of one method.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 1996
Entirely since publication
All 331 months of our record post-date the 1996 paper.
Sharpe -0.16-4.7% p.a.January 1999July 2026

There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
46%
12 of 26 3-year windows made money
Worst window
-0.80
Sharpe, January 2012 – December 2014
January 1999July 2026
Median Sharpe
-0.07
Dispersion
0.40
Best window
0.59

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.34.7%-2.5%
3 yearsp.a.10.5%-11.2%
5 yearsp.a.7.4%-5.1%
10 yearsp.a.10.2%-4.7%
Since inceptionp.a.7.9%-11.2%
Calendar years
YearLong legLong-short
20267 mo7.7%-1.9%
202514.7%-23.7%
20244.5%-5.6%
20233.9%-6.5%
2022-1.5%-0.5%
202125.9%18.8%
202013.6%-6.2%
201915.7%-21.0%
20184.5%21.8%
201723.2%-6.0%
2016-0.8%5.7%
20154.8%-7.9%
201424.6%-13.7%
201341.0%-11.0%
201217.9%-25.6%
201110.9%17.7%
20102.9%-6.2%
200918.9%-3.0%
2008-21.5%7.5%
20076.7%10.4%
20066.0%1.4%
20055.4%16.4%
20044.4%9.2%
200312.4%-33.6%
2002-19.5%41.5%
2001-13.2%16.9%
200033.4%-84.5%
1999-4.3%-63.3%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FROH
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.45% (placeholder)
Inception2022-05-05 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$3.09T

Methodology

The Foundry Healthcare Return on Equity Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Return on Equity signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.